文献速递眼底病与葡萄膜炎

法瑞西单抗治疗相关的眼内炎症:一年真实世界结局

INTRAOCULAR INFLAMMATION ASSOCIATED WITH FARICIMAB THERAPY: One-Year Real-World Outcomes.
PubMed 文献 · Retina · 2025-01-01

眼内炎症发生率为每注射0.19%、每眼0.86%、每患者0.86%,多发生于前几次注射(中位3.5次),均为前葡萄膜炎,4眼(20%)伴玻璃体炎,无后葡萄膜炎或视网膜血管阻塞。

要点

  • 眼内炎症估计发生率为每注射0.19%(95%CI 0.12-0.30)、每眼0.86%(95%CI 0.53-1.33)、每患者0.86%(95%CI 0.49-1.39)。
  • 眼内炎症多发生于前几次注射(中位3.5次,范围1-10次),所有病例表现为前葡萄膜炎,4眼(20%)伴玻璃体炎。
  • 未报告后葡萄膜炎或视网膜血管阻塞病例,眼内炎症事件前后平均视力无统计学显著差异(0.40 vs 0.378 logMAR,P=0.26)。

核心结论

  • 在此真实世界报告中,法瑞西单抗耐受性良好,眼内炎症相关不良事件发生率与注册临床试验中观察到的结果一致。
  • 不良事件总体较轻,预后良好。

研究设计与样本

  • 回顾性审查Moorfields眼科医院2022年9月1日至2023年8月31日接受法瑞西单抗治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿患者的电子病历。
  • 主要结局为眼内炎症(排除眼内炎)的发生率。

主要发现

  • 共20眼(16例患者)发生至少1次眼内炎症不良事件。
  • 眼内炎症估计发生率为每注射0.19%(95%CI 0.12-0.30)、每眼0.86%(95%CI 0.53-1.33)、每患者0.86%(95%CI 0.49-1.39)。
  • 眼内炎症多发生于前几次注射(中位3.5次注射,范围1-10次)。
  • 所有病例表现为前葡萄膜炎,4眼(20%)伴玻璃体炎;未报告后葡萄膜炎或视网膜血管阻塞证据。
  • 眼内炎症事件前后平均视力分别为0.40和0.378最小分辨角对数,无统计学显著差异(P=0.26)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report 1-year real-world evidence on intraocular inflammation (IOI) adverse events in patients undergoing faricimab therapy in a tertiary care hospital. METHODS: A retrospective review of electronic medical records was conducted for patients receiving faricimab treatment for neovascular age-related macular degeneration and diabetic macular edema at Moorfields Eye Hospital between September 1, 2022, and August 31, 2023. The primary outcome was the incidence of IOI (excluding endophthalmitis). RESULTS: Two thousand three hundred and eighteen eyes from 1,860 patients were included and underwent a total of 10,297 injections. A total of 20 eyes (16 patients) had ≥1 adverse event of IOI. Estimated incidence of IOI was 0.19% per injection (95% confidence interval, 0.12-0.30), 0.86% per eye (95% confidence interval 0.53-1.33), and 0.86% per patient (95% confidence interval, 0.49-1.39). Intraocular inflammation mostly occurred within the first injections (median 3.5 injections, range 1-10). All cases presented with anterior uveitis and were associated with vitritis in four eyes (20%). No cases of posterior uveitis or evidence of retinal vascular occlusion were reported. There was no statistically significant difference between the mean visual acuity before and after IOI event (0.40 and 0.378 logarithm of minimum angle of resolution, respectively, P = 0.26). CONCLUSION: In this real-world report, faricimab was well tolerated with an incidence of IOI-related adverse events consistent to that observed in registration trials. The adverse events were generally mild and had a favorable prognosis.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Montesel A, Sen S, Preston E, et al. INTRAOCULAR INFLAMMATION ASSOCIATED WITH FARICIMAB THERAPY: One-Year Real-World Outcomes. Retina. 2025. PMID: 39761510. doi:10.1097/IAE.0000000000004394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。